XBIT - エックスバイオテック (XBiotech Inc.) エックスバイオテック

 XBITのチャート


 XBITの企業情報

symbol XBIT
会社名 XBiotech Inc (エックスバイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Xバイオテック(XBiotech Inc)は臨床段階のバイオ医薬品会社である。同社は各種疾患の治療のために「True Human」モノクローナル抗体の発見と開発に従事する。同社は天然ヒト免疫応答に由来するリード製品候補であるXilonix(MABp1)に焦点を当てる。同社はまた、「True Human」モノクローナル抗体発見プラットフォーム及び製造システムを開発した。Xilonixはインターロイキン-1アルファ(IL-1a)を特異的に中和する治療用抗体である。同社のパイプラインは、癌、血管疾患、炎症性皮膚疾患及び糖尿病等の疾患を治療するための各種ヒト抗体を含む。同社は症候性結腸直腸癌の治療のためにヨーロッパにおいて第III相試験を完了した。同社はまた、血管疾患、II型糖尿病、ざ瘡、乾癬、膿皮症(PG)及び腹水炎(HS)を含む他の炎症状態の臨床試験において、リード製品候補を調査した。   エックスバイオテックはカナダ籍の臨床段階のバイオ医薬品メ―カ―。種々の疾患の治療のための、モノクロ―ナル抗体「True Human」を発見し、パイプラインと生産システムを開発。主要製品候補、インタ―ロイキン-1アルファを中和する治療抗体「MABp1」の開発に注力する。本社は米国テキサス州。   
本社所在地 8201 E. Riverside Drive Building 4 Suite 100 Austin TX 78744 USA
代表者氏名 John Simard ジョン・シマール
代表者役職名 Chairman of the Board President Chief Executive Officer Founder
電話番号 +1 512-386-2930
設立年月日 38412
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 51人
url www.xbiotech.com
nasdaq_url https://www.nasdaq.com/symbol/xbit
adr_tso
EBITDA EBITDA(百万ドル) -21.78000
終値(lastsale) 3.21
時価総額(marketcap) 114981468.12
時価総額 時価総額(百万ドル) 116.41430
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 91.56530
当期純利益 当期純利益(百万ドル) -23.43000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 XBiotech Inc revenues was not reported. Net loss decreased 49% to $10M. Lower net loss reflects Research and Development decrease of 60% to $4.6M (expense) Salaries and related expenses decrease of 48% to $2.1M (expense) Stock-based Compensation in General decrease of 69% to $497K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.58 to -$0.28.

 XBITのテクニカル分析


 XBITのニュース

   XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall  2020/08/24 20:27:51 ABC News
Stocks that moved heavily or traded substantially Monday: XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall
   XBiotech Discovers COVID-19 Candidate Therapy  2020/08/17 12:20:00 GlobeNewswire
The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood
   XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy  2020/07/22 13:20:00 GlobeNewswire
After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021
   XBiotech antibody shows potential for treating stroke-related brain injury (NASDAQ:XBIT)  2020/07/14 14:32:18 Seeking Alpha
XBiotech (XBIT +2.6%) announces encouraging results from research conducted in Switzerland that supports the rationale of interleukin-1 alpha (IL-1⍺) block
   XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke  2020/07/14 13:25:00 GlobeNewswire
Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy
   XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall  2020/08/24 20:27:51 ABC News
Stocks that moved heavily or traded substantially Monday: XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall
   XBiotech Discovers COVID-19 Candidate Therapy  2020/08/17 12:20:00 GlobeNewswire
The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood
   XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy  2020/07/22 13:20:00 GlobeNewswire
After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021
   XBiotech antibody shows potential for treating stroke-related brain injury (NASDAQ:XBIT)  2020/07/14 14:32:18 Seeking Alpha
XBiotech (XBIT +2.6%) announces encouraging results from research conducted in Switzerland that supports the rationale of interleukin-1 alpha (IL-1⍺) block
   XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke  2020/07/14 13:25:00 GlobeNewswire
Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy
   XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall  2020/08/24 20:27:51 ABC News
Stocks that moved heavily or traded substantially Monday: XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall
   XBiotech Discovers COVID-19 Candidate Therapy  2020/08/17 12:20:00 GlobeNewswire
The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood
   XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy  2020/07/22 13:20:00 GlobeNewswire
After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021
   XBiotech antibody shows potential for treating stroke-related brain injury (NASDAQ:XBIT)  2020/07/14 14:32:18 Seeking Alpha
XBiotech (XBIT +2.6%) announces encouraging results from research conducted in Switzerland that supports the rationale of interleukin-1 alpha (IL-1⍺) block
   XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke  2020/07/14 13:25:00 GlobeNewswire
Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エックスバイオテック XBIT XBiotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)